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The F box protein Skp2 is frequently overexpressed in human tumors and is capable of transforming cultured 
cells in vitro. It has been assumed, quite reasonably, that this oncogenic property of Skp2 is directly related 
to its role, as part of an SCF ubiquitin ligase complex, in the ubiquitin-mediated proteolysis of negative 
cell cycle regulatory proteins, notably p27Kip1. However, building on earlier results indicating that silencing 
of Skp2 promotes apoptosis in some tumor-derived cell lines, Kitagawa and coworkers in the February 1 
issue of Molecular Cell have elucidated an alternative mechanism for promotion of tumorigenesis by Skp2, 
specifically the suppression of p53-mediated apoptosis.Evolution at the molecular level works 
in strange ways. There is abundant evi-
dence that a protein perfected by evolu-
tion for a particular molecular role can 
suddenly assume a completely unre-
lated function. Presumably, all that’s 
required is a mutation that creates a 
novel protein-protein interaction. If an 
advantage is gained, this interaction 
will be optimized by further evolutionary 
pressure. If distinct surfaces of the pro-
tein are involved in the respective inter-
actions, the new function might arise 
without even detracting from the effi-
ciency of the original function, creating 
a truly bifunctional protein. The recent 
report of a proteolysis-independent role 
for the F box protein Skp2 may be a 
case in point (Figure 1).
Skp2 (S phase kinase-associated 
protein 2) has been well character-
ized as one of several substrate-bind-
ing adapters for SCF family ubiquitin 
ligases (reviewed in Deshaies, 1999). F 
box proteins such as Skp2 contain two 
critical functional domains, an F box for 
integration into the SCF ligase core and 
a substrate-binding domain composed 
of any of a number of protein-protein 
interaction motifs. In the case of Skp2 
the protein-protein interaction domain 
contains a series of iterations of a motif 
known as a leucine-rich repeat that, 
along with a small cofactor protein Cks1, 
forms the substrate-binding surface for 
the ubiquitin ligase (Hao et al., 2005). In 
this manner SCFSkp2 targets a number 
of important negative regulators of the 
cell cycle: p21Cip1, p27Kip1, p57Kip2, and a 88 Cancer Cell 13, February 2008 ©2008 Elsmember of the retinoblastoma protein 
family, p130 (reviewed in Nakayama 
and Nakayama, 2006; Reed, 2006). It 
has therefore been proposed that the 
oncogenicity of Skp2 is implemented by 
depriving tumor cells of multiple critical 
cell cycle braking mechanisms, allow-
ing for unchecked proliferation. It is cer-
tainly likely that Skp2 does contribute to 
oncogenesis via this mechanism in at 
least some cancers. However, another 
dark side of the cancer phenotype is 
the stubborn refusal of malignant cells 
to die. The impetus for the current work 
derives from the observation made in 
a number of laboratories that silencing 
of Skp2 by RNAi led specifically to kill-
ing of some cancer-derived cell lines 
by programmed cell death (apoptosis) 
(Lee and McCormick, 2005). Since 
this dependency on Skp2 for survival 
could not easily be explained simply 
by accumulation of cell cycle inhibitors, 
Kitagawa and coworkers (Kitagawa et 
al., 2008) searched for a mechanism 
integrally linked to apoptotic path-
ways. Remarkably, they found that 
Skp2 interferes directly with activation 
of p53, the transcription factor effector 
of the stress-responsive apoptotic pro-
gram (Vousden and Lu, 2002). Equally 
remarkably, this function appears to be 
independent of SCF-mediated proteoly-
sis, as an F box-deleted version of Skp2 
that can’t associate with SCF core is 
equally potent as a p53 attenuator.
Kitagawa and coworkers have car-
ried out some nice molecular detective 
work to elucidate the mechanism. Spe-evier Inc.cifically, Skp2 binds the transcriptional 
coactivator p300, thereby competitively 
blocking its interaction with p53. Since 
acetylation of p53 by p300 is critical for 
p53 activation (reviewed in Grossman, 
2001), Skp2 is a dosage-dependent 
inhibitor of p53 transactivation function. 
Consistent with this being an acquired 
proteolysis-independent mode of action 
of Skp2, it is the amino terminus of the 
protein that binds p300, upstream of the 
F box and leucine-rich repeats required 
for ubiquitin ligase activity. On the other 
hand, Skp2 binds to the CH1 and CH3 
domains near the amino terminus of 
p300, which are not surprisingly also 
involved in p53 binding.
This is not a new strategy for dis-
abling p53. The adenoviral oncoprotein 
E1A binds to the CH3 domain of p300, 
preventing activation of p53 during viral 
infection. Mdm2, another antagonist 
of p53 function, also binds to p300, 
thereby blocking interaction with p53. In 
each of these cases, it is easy to ratio-
nalize p53 inhibition within the expres-
sion context of the respective protein. 
Neutralization of p53 by E1A is required 
to facilitate viral DNA replication and to 
preserve the integrity of the host cell 
during viral infection. Mdm2 is part of 
a negative feedback loop that limits the 
duration of the p53 response. This then 
raises the question of what the biologi-
cal role of p53 antagonism by Skp2 is. 
Unfortunately, no completely compelling 
model is forthcoming, particularly when 
it comes to explaining Skp2-mediated 
protection from apoptosis.
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for the Skp2-p53 regulatory relation-
ship derives from observations on the 
regulation of Skp2 expression through 
the cell cycle. Transcription of Skp2 is 
under control of the Rb-E2F system, 
and therefore Skp2 is only expressed 
at and after the G1/S phase transition, 
when Rb becomes hyperphospho-
rylated by cyclin-dependent kinases 
(CDKs). Activation of p53 by a variety 
of stresses has been shown to inhibit 
G1 CDK activity, thereby preventing Rb 
phosphorylation and E2F-dependent 
transcription, ultimately conferring G1 
arrest. Activation of p53 in G1 would 
therefore promote a “low-Skp2” envi-
ronment stabilizing and reinforcing the 
p53-active state. However, increased 
Skp2 synthesis would be indicative of 
decay of the p53-active state, as it would 
reflect loss of Rb-mediated inhibition of 
E2F-dependent transcription. Perhaps, 
then, Skp2-mediated inactivation of p53 
serves as a mechanism for generating 
a decisive G1 to S phase transition by 
accelerating and stabilizing an alterna-
tive p53-inactive state. The parallel role 
of Skp2 in ubiquitin-mediated prote-
olysis of CDK inhibitors p21, p27, p57, 
and p130 also fits this “two metastable 
states” paradigm.
Whatever the intended role of Skp2 
in the regulation of p53, it is evident 
that this becomes subverted during the 
course of oncogenesis. As is the case 
of Mdm2 (Hdm2 in humans) another 
p53 antagonist, Skp2 is frequently over-
expressed in tumors, and overexpres-
sion correlates with particularly aggres-
sive disease (e.g., Shapira et al., 2005). 
The link between Skp2 and suppression 
of p53-mediated apoptosis provides a 
plausible explanation for Skp2 selec-
tion during oncogenesis. p53 action 
poses a formidable barrier to malig-
nancy, as is evidenced by the obser-
vation that 50% of human tumors are 
mutated for p53. Presumably the other 
50% need to abrogate p53 function by 
alternative means. The requirement to 
neutralize p53 during oncogenesis is 
best explained by the recently devel-
oped concept known as “oncoprotein-
induced stress” (reviewed in Bartek et 
al., 2007). Cells possess mechanisms 
that sense abnormally strong prolif-
erative or replicative signals. These are then processed via a p53-dependent 
pathway to promote either apoptosis 
or a senescence-like state, depending 
on the cell type or the signal amplitude. 
Once p53 is lost, or its function attenu-
ated, the probability of a cell becom-
ing malignant is greatly increased. It is 
likely, therefore, that overexpression of 
Skp2 is one means to this end. Skp2-
mediated attenuation of p53 function 
may also come into play at another 
key juncture in the life a tumor. Virtu-
ally all successful strategies of chemo-
therapy depend on a robust apoptotic 
response in the targeted tumor. Clearly, 
based on the current work, overexpres-
sion of Skp2 in p53-positive tumors is 
likely to promote resistance to therapy. 
Indeed, Kitagawa and coworkers show 
that ectopic expression of Skp2 renders 
figure 1. Dual function for Skp2
In the absence of Skp2, p300 associates with and 
acetylates p53, creating an environment permis-
sive for p53 activation, which leads to apoptosis 
and cell cycle arrest in response to stress. CDK 
inhibitors, p21, p27, p57, and p130 are also sta-
ble in the absence of Skp2, also promoting cell 
cycle arrest. Crosstalk between these systems is 
indicated, as p53 activation leads to upregulation 
of p21. Upon expression of Skp2, either in the 
context of cell cycle progression or during the 
course of oncogenesis, both of these pathways 
are negatively regulated. The amino-terminal 
domain (ATD) of Skp2 binds to p300, prevent-
ing association with p53, thereby preventing its 
activation. This activity of Skp2 promotes sur-
vival and proliferation in response to stress. Skp2 
also serves as the substrate-binding subunit of 
an SCF ubiquitin ligase that along with E1, E2, 
and ubiquitin promotes the ubiquitin-dependent 
proteolysis of CDK inhibitors p21, p27, p57, and 
p130, stimulating proliferation. Skp2 binds the 
SCF core via its F box (F) and binds substrates 
through its leucine-rich repeats (LRRs).Cancer Cetumor-derived cells resistant to killing 
by genotoxic drugs. It is therefore rea-
sonable to ask whether targeting Skp2 
or the Skp2-p300 interaction might 
enhance the efficiency of chemotherapy 
for p53-positive cancers. With respect 
to the Skp2-p300 interaction, the pos-
sibility of developing a small-molecule 
inhibitor depends on the nature of the 
interface between the two proteins, 
which has not yet been determined. 
Current dogma dictates that only con-
tacts involving deep pockets or clefts 
are accessible to small-molecule inter-
ference. On the other hand, recent 
advances in the application of RNAi 
technology to tumors (reviewed in Masi-
ero et al., 2007) may eventually permit a 
strategy of direct targeting of Skp2. This 
approach would have the advantage of 
eliminating all of the potentially pro-
oncogenic functions of Skp2, including 
its role in the proteolysis of cell cycle 
inhibitors. Whatever the approach to be 
employed, the findings of Kitagawa and 
coworkers increase the profile of Skp2 
as a therapeutic target worthy of further 
investigation.
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